ArticleClinical journal of the American Society of Nephrology : CJASN2021
Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.Journal of the American Society of Nephrology : JASN · 2026Article
- Acute tubular injury versus acute interstitial nephritis in the kidney precision medicine project.JCI insight · 2026Observational
- Interferon-Inducible Gene Upregulation Correlates With Successful Viral Clearance in Patients With BK Polyomavirus-Associated Nephropathy.Kidney international reports · 2026Article
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- Molecular Diagnostics Supporting a ≥35% Diffuse Peritubular Capillaritis Extent Threshold for Diagnosis of AMR-A Retrospective Dual Center Study.International journal of molecular sciences · 2025Article
- Urgent considerations on renal immune-related adverse events in oncology practice.Frontiers in immunology · 2025Review
- Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.Clinical kidney journal · 2024Review
- Elucidating the role of Pyroptosis in papillary thyroid cancer: prognostic, immunological, and therapeutic perspectives.Cancer cell international · 2024Article
- Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Immune checkpoint inhibitors and acute kidney injury.Frontiers in immunology · 2024Review
- Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?Clinical kidney journal · 2023Article
- Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease.Immunological reviews · 2023Review
- Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis.The Journal of clinical investigation · 2023Article
- Review
- Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor-Induced Kidney Injury.Cancers · 2022Article
- Immunotherapies and Renal Injury.Current opinion in toxicology · 2022Article
- Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.Korean journal of transplantation · 2022Review
- Transplant Onconephrology in Patients With Kidney Transplants.Advances in chronic kidney disease · 2022Review
- Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?Frontiers in medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
Abstract
BACKGROUND AND
objectivesImmune checkpoint inhibitors are increasingly used to treat various malignancies, but their application in patients with kidney transplants is complicated by high allograft rejection rates. Immune checkpoint inhibitor-associated rejection is a novel, poorly understood entity demonstrating overlapping histopathologic features with immune checkpoint inhibitor-associated acute interstitial nephritis, which poses a challenge for diagnosis and clinical management. We sought to improve the understanding of these entities through biopsy-based gene expression analysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: NanoString was used to measure and compare the expression of 725 immune-related genes in 75 archival kidney biopsies, including a 25-sample discovery cohort comprising pure T cell-mediated rejection and immune checkpoint inhibitor-associated acute interstitial nephritis and an independent 50-sample validation cohort comprising immune checkpoint inhibitor-associated acute interstitial nephritis, immune checkpoint inhibitor-associated T cell-mediated rejection, immune checkpoint inhibitor-associated crescentic GN, drug-induced acute interstitial nephritis, BK virus nephropathy, and normal biopsies.
resultsSignificant molecular overlap was observed between immune checkpoint inhibitor-associated acute interstitial nephritis and T cell-mediated rejection. Nevertheless,
conclusionsThese results indicate that, although there is significant molecular similarity between immune checkpoint inhibitor-associated rejection and acute interstitial nephritis, biopsy-based measurement of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.